Loading
A phase 1/2 trial of Fulvestrant, Letrozole in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07288359 by Novartis Pharmaceuticals, with 205 participants planned, started 2025-12-29 and due to reach its primary completion in 2031-05-09. Interventions recorded: GVV858, Fulvestrant, Letrozole. Conditions listed: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Prostate cancer.
Shares Letrozole (and other aromatase inhibitors), Fulvestrant.
Shares Fulvestrant, Novartis.
Shares Novartis, Prostate cancer.
Shares Novartis, Prostate cancer.
Shares Novartis, Prostate cancer.
Shares Novartis, Prostate cancer.
Shares Novartis, Prostate cancer.